- Delong Liu, New York Medical College
Society affiliationsJournal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Letter to the Editor
Article collection on selective inhibitors of nuclear export (SINE)
Research: XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
Journal of Hematology & Oncology 2014, 7:46 (5 October 2014)
Editorial: SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents
Journal of Hematology & Oncology 2014, 7:67 (4 October 2014)
Editorial: Selective inhibitors of nuclear export (SINE) in hematological malignancies
Experimental Hematology & Oncology 2015, 4:7 (1 March 2015)
Review: Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
Journal of Hematology & Oncology 2014, 7:78 (15 October 2014)
Review: Nucleo-cytoplasmic transport as a therapeutic target of cancer
Journal of Hematology & Oncology 2014, 7:85 (5 December 2014)
Aims & scope
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.
Experimental Hematology & Oncology
Submit your research to our sister journal, Experimental Hematology & Oncology
Prof Delong Liu
“Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists.”
Journal of Hematology & Oncology is now publishing Research Highlights, commentaries on recently published work that place the new research in the context of the current literature.
Kim and Slack highlight a selection of studies that have contributed to our understanding of the molecular mechanisms and clinical relevance of KRAS regulation by miRNAs.
Medina and colleagues discuss synthetic lethal interactions involving several proteins of the SWI/SNF complex that have opened the possibility of new cancer therapeutic approaches.
Journal of Hematology & Oncology 2015, 8:20
Roles of microRNAs and other noncoding RNAs in cancer
Published: 26 November 2014
Last updated: 28 March 2015